ClinicalTrials.Veeva

Menu

Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia

Imperial College London logo

Imperial College London

Status

Withdrawn

Conditions

Telangiectasia, Hereditary Hemorrhagic

Study type

Observational

Funder types

Other

Identifiers

NCT00733629
IC/CLS4

Details and patient eligibility

About

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels. We propose to culture endothelial cells from patients with HHT, to culture cells that express the proteins mutated in HHT, namely endoglin and ALK-1. We will study the properties of these cells which will involve their growth in different conditions and anticipate that DNA, mRNA and proteins will be extracted from these cells for study of cell responses and association with expression levels of endoglin and ALK-1. We hypothesize that these cells which express "half-normal" endoglin or ALK-1 will show altered protein synthetic differences when compared to normal white blood cells. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with hereditary haemorrhagic telangiectasia and family members

Exclusion criteria

  • Unable to provide informed consent

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems